1379401
USP
美洛昔康
United States Pharmacopeia (USP) Reference Standard
别名:
4-羟基-2-甲基- N -（5-甲基-2-噻唑基）-2 H -1,2-苯并噻嗪-3-甲酰胺 1,1-二氧化物
等级
pharmaceutical primary standard
API类
meloxicam
制造商/商品名称
USP
应用
pharmaceutical (small molecule)
包装形式
neat
InChI
1S/C14H13N3O4S2/c1-8-7-15-14(22-8)16-13(19)11-12(18)9-5-3-4-6-10(9)23(20,21)17(11)2/h3-7,19H,1-2H3,(H,15,16)/b13-11+
InChI key
DWMREKMVXIFPFM-ACCUITESSA-N
正在寻找类似产品? 访问 产品对比指南
一般描述
本产品按照发行药典的发行和规定提供。支持本产品的所有信息，包括安全数据表和任何产品信息传单，都是在发行药典的授权下开发和发布的。如需进一步信息和支持，请访问现行药典网站。
应用
美洛昔康USP参标准品，预期用途是USP规定的指定质量测试和检测。也用于USP各论，例如：
- 美洛昔康口服混悬液
- 美洛昔康片
分析说明
这些产品仅供测试和化验使用。它们不适用于人类或动物，也不能用于诊断、治疗或治愈任何类型的疾病。
其他说明
可能适用相应的销售限制。
警示用语：
Danger
危险声明
危险分类
Acute Tox. 3 Oral
储存分类代码
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
WGK
WGK 2
闪点(°F)
Not applicable
闪点(°C)
Not applicable
G Engelhardt
British journal of rheumatology, 35 Suppl 1, 4-12 (1996-04-01)
This review focuses on the key pharmacological findings with a new NSAID, meloxicam. Unlike established NSAIDs, it preferentially inhibits inducible COX-2 in guinea-pigs peritoneal macrophages and human COX-2 in COS cells. Compared with other NSAIDs, meloxicam is the most potent
D Türck et al.
British journal of rheumatology, 35 Suppl 1, 13-16 (1996-04-01)
Meloxicam is a new preferential cyclooxygenase-2 (COX-2) inhibitor currently for the treatment of osteoarthritis and rheumatoid arthritis. Its pharmacokinetic profile is characterized by a prolonged and almost complete absorption and the drug is > 99.5% bound to plasma proteins. Meloxicam
[Meloxicam (Movalis)].
Dusanka Martinović Kaliterna
Reumatizam, 54(2), 81-82 (2008-03-21)
D E Furst
Seminars in arthritis and rheumatism, 26(6 Suppl 1), 21-27 (1997-06-01)
Nonsteroidal antiinflammatory drugs (NSAIDs) exert their actions by inhibiting cyclooxygenase (COX). It has recently been postulated that NSAIDs' antiinflammatory efficacy arises from inhibition of the COX-2 isoform of cyclooxygenase, whereas inhibition of the COX-1 isoform produces the troublesome and sometimes
[The new nonsteroidal anti-inflammatory preparation meloxicam in the treatment of rheumatoid arthritis].
E I Grishina
Likars'ka sprava, (2)(2), 19-25 (1997-03-01)
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持